5. AI is Changing Pharma's Commercial Strategy

AI-powered care coordination is transforming how patients and healthcare professionals interact at the point of care, creating unprecedented care journeys and opening up new opportunities for pharma to engage with patients. Earlier detection means more patients are being diagnosed and treated for diseases — good news for patients and pharma brands alike. It’s therefore imperative for pharma brands to understand how AI is reshaping their commercial strategies.

?? The Latest

Pharma is embracing AI for data insights and commercial strategies, but there's untapped potential at the point of care . With 82% of healthcare leaders noting meaningful AI-driven improvements, pharma companies can leverage point-of-care AI to enhance patient-centricity, address healthcare disparities, and optimize workflows, ultimately driving brand growth and better health outcomes.

AI has changed how care is being delivered in our hospitals with real-world impacts for patients — but that's just the beginning! Read the predictions experts have when it comes to AI applied in healthcare — discussing what we can automate to uncover the true value of AI for clinicians, patients, and pharma stakeholders.

AI is revolutionizing how HCPs care for patients. In a recent study published in Nature Medicine, physicians receiving AI-powered ECG alerts were able to better identify and treat high-risk patients vs. physicians following conventional care procedures. AI-powered care aids in early identification of high-risk patients and prompts timely clinical intervention . Plus, read Cardiologist and author, Eric Topol, MD 's take on why medical AI is lifesaving .

?? Viz News

?? Our CEO, Dr Chris Mansi recently joined the World Economic Forum ’s podcast Radio Davos to discuss the critical need for AI to empower rather than exclude , particularly for those with disabilities.

?? For the second year in a row, Viz.ai has been awarded an Edison Award for our Viz Pulmonary Embolism solution .

?? We’re excited to be collaborating with the Hypertrophic Cardiomyopathy Association (HCMA) to improve care for hypertrophic cardiomyopathy (HCM) patients. Read about our FDA approved HCM module, deployment of which is financially supported by a multi-year agreement with Bristol Myers Squibb .

?? Vizion

?? Health systems recognize the benefits of digital and AI transformation in addressing workforce challenges, reducing costs, and enhancing overall care quality, with projected net savings of up to $360 billion in healthcare spending. Despite this interest, 75% of health system leaders desire more ways to innovate but lack the planning and execution capabilities to do so .

?? Scientists have proposed an AI model that can automatically analyze CT volumes and integrate them with patient characteristics to predict mortality after transcatheter aortic valve replacement (TAVR) . The AI advantage is speed without losing accuracy.

?? Over two-thirds of all deaths in the US can be attributed to just five chronic conditions: heart problems, cancer, stroke, chronic obstructive pulmonary disease, and diabetes — exacerbated by an increasingly overwhelmed healthcare workforce — but AI can help, starting with the very first step of effective care: diagnosis .

AI is poised to revolutionize healthcare by enhancing diagnostic accuracy, automating administrative tasks, and supporting physician decision-making, though it will complement rather than replace the critical human elements of empathy and complex judgment in patient care.?Read Harvard Medical School’s take .

?? Data

If you haven’t read 麦肯锡 's insights on the challenges and opportunities for modernizing biopharma commercial models to boost patient value — from improving access to therapy to embracing AI. Grab a cup of coffee and dive in to learn how many biopharma companies have already begun transforming commercial activities using AI models—for example, with “next best action” suggestions.

?? Events

?? Reuters Pharma: Point-of-care AI: The new imperative for pharma commercial strategy Watch our recent webinar to learn why point-of-care AI is the new imperative for pharma commercial strategy.

??? Contributors

Get in touch with Tom Krohn and Sherie Zhou

Copyright ? 2024 Viz.ai

548 Market St., # 21826, San Francisco, CA 94104

Between issues, keep current with the latest updates from Viz.ai by following us on LinkedIn and by subscribing to the insider version of Innovizion, sent bi-monthly directly to your inbox from us. [add link to landing page]

About Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,600+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai OneTM is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai .